DexCom (DXCM) reported strong Q2 2026 results with gross margin expanding to 64.1% and operating margin at 25.1%, driven by manufacturing efficiencies and G7 15-day product transition. However, near-term profitability could face pressure from Ireland factory ramp-up costs, forex headwinds, and higher oil-linked input costs. The company maintains a Zacks Rank #3 (Hold) rating with shares up 29.4% year-to-date.

AxoGen (AXGN) has declined 22.6% over four weeks and is now in oversold territory with an RSI reading of 27.04, suggesting a potential reversal. Wall Street analysts have raised earnings estimates by 2.2% over the past 30 days, and the stock holds a Zacks Rank #2 (Buy) rating, indicating potential for near-term price appreciation.

Axogen announced a definitive agreement to acquire BioCircuit Technologies for $200 million in cash, adding NerveTape™, the first FDA-approved sutureless device for peripheral nerve repair. The acquisition is expected to close in Q4 2026 and be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in the first year, while maintaining positive free cash flow. Axogen will fund the purchase through a $208.7 million public stock offering.

Axogen, Inc. announced that management will participate in three investor conferences in March 2026: Raymond James 47th Annual Institutional Investors Conference (March 3), Leerink Global Healthcare Conference (March 9), and The Citizens Life Sciences Conference (March 10). The company will present and hold 1x1 investor meetings at these events, with webcasts available on its investor relations website.

Axogen, Inc. (Nasdaq: AXGN), a peripheral nerve repair solutions company, announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026, followed by a management conference call and webcast at 8:00 a.m. ET. The company invites investors to participate via phone or live webcast.

Axogen, Inc. announced an upsized underwritten public offering of 4 million shares at $31.00 per share, expected to raise approximately $124 million in gross proceeds. The company plans to use the net proceeds to pay off its term loan facility with Oberland Capital, along with working capital and capital expenditures. The offering is expected to close on January 23, 2026.

Axogen reported preliminary full-year 2025 revenue of approximately $225.2 million, representing 20.2% growth over 2024, with Q4 2025 revenue expected at $59.9 million (21.3% increase). The company achieved FDA Biologics License Application approval for Avance® on December 3, 2025, and expects gross margins above 74%. Cash position improved by approximately $6.0 million to $45.5 million by year-end 2025.

Axogen received FDA Biologics License Application approval for AVANCE, an acellular nerve scaffold for treating peripheral nerve discontinuities in patients aged 1 month and older, with commercial availability expected in early Q2 2026.

The Schall Law Firm is investigating potential securities law violations by Axogen, Inc. after the company's stock dropped over 9% following an FDA application extension announcement for its Avance® Nerve Graft.

The global amniotic membrane market is expected to grow at a 7% CAGR by 2032, driven by increasing demand for advanced wound healing treatments and ophthalmological applications, with North America leading market expansion.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will report its 2024 fourth quarter and full year financial results on February 25, 2025. The company will host an investment-community conference call and webcast to discuss the results.

Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a company known for its development in biosensors. The acquisition is expected to strengthen Bruker's position in the pharma and biotech industries by leveraging its leading high-throughput Surface Plasmon Resonance portfolio and Dynamic Biosensors' unique instruments.